Heron Therapeutics, INC /DE/ Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Rubric Capital Management LP and David Rosen increased their beneficial ownership in Heron Therapeutics, Inc. to 15.9% following the conversion of preferred stock and a convertible note issuance.
NASDAQ
Heron Therapeutics has entered into a series of agreements, including a $66.38 million capital raise through common stock, preferred stock, and convertible notes, alongside a governance agreement granting a board seat to Rubric Capital Management LP.